Senores Pharmaceuticals Ltd vs Shukra Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Senores Pharmaceuticals Ltd is ₹ 1116 as of 18 May 14:38 . The P/E Ratio of Senores Pharmaceuticals Ltd changed from 45 on March 2025 to 45 on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Shukra Pharmaceuticals Ltd changed from 0 on March 2022 to 0 on March 2025 . This represents a CAGR of 0.0% over 4 years The Market Cap of Senores Pharmaceuticals Ltd changed from ₹ 2637 crore on March 2025 to ₹ 2637 crore on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Shukra Pharmaceuticals Ltd changed from ₹ 0 crore on March 2022 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 4 years The revenue of Senores Pharmaceuticals Ltd for the Mar '26 is ₹ 192.86 crore as compare to the Dec '25 revenue of ₹ 178.34 crore. This represent the growth of 8.14% The revenue of Shukra Pharmaceuticals Ltd for the Mar '26 is ₹ 7.27 crore as compare to the Dec '25 revenue of ₹ 39.95 crore. This represent the decline of -81.8% The ebitda of Senores Pharmaceuticals Ltd for the Mar '26 is ₹ 65.16 crore as compare to the Dec '25 ebitda of ₹ 57.79 crore. This represent the growth of 12.75% The ebitda of Shukra Pharmaceuticals Ltd for the Mar '26 is ₹ 1.65 crore as compare to the Dec '25 ebitda of ₹ 27.95 crore. This represent the decline of -94.1% The net profit of Senores Pharmaceuticals Ltd changed from ₹ 16.43 crore to ₹ 36.67 crore over 8 quarters. This represents a CAGR of 49.40% The net profit of Shukra Pharmaceuticals Ltd changed from ₹ 3.16 crore to ₹ -1.72 crore over 8 quarters. This represents a CAGR of NaN% The Dividend Payout of Senores Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Shukra Pharmaceuticals Ltd changed from 10.47 % on March 2022 to 4.57 % on March 2025 . This represents a CAGR of -18.72% over 4 years .

About Senores Pharmaceuticals Ltd

Senores Pharmaceuticals Limited was originally incorporated as 'Senores Pharmaceuticals Private Limited' through a Certificate of Incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.
Thereafter, the name of the Company was changed to 'Senores Pharmaceuticals Limited' upon conversion to a Public Limited Company and a fresh Certificate of Incorporation dated September 4, 2023, was issued by the RoC to the Company. Senores Pharma is a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms.
The Regulated Markets business is focused on Regulated Markets of US and Canada.
The Company has adopted a strategy of identifying, developing and commercializing specialty and complex niche products in the mid-market range and received approvals for 19 ANDAs.

About Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Limited, formerly known Relish Pharmaceuticals Limited was established in March, 1993 and later on the Company name was changed from Relish Pharmaceuticals Limited to Shukra Pharmaceuticals Limited effective on September 22, 2016.
The Company is presently engaged in the business of manufacturing and trading of pharmaceuticals formulations and laboratory testing. The company provides varieties of products to the clientele.
Their product portfolio includes Antibiotics (Penicillin), Anti Biotics (Cephalosporin), Anti Biotics, Macrolides, Quinolones, Anti Bacterial, Anti Fungal, Anti Malarial, Anti Viral, Anti Protozoal, Anti Anthelmintic, Sedative and Tranquilliser, Anti Depressant, Anti Manic, Anti Emetic, Anti Ulcer, Beta Blockers, Diuretics, Analgesic, Analgesic (NASID), Muscle Relaxants, Anti Tuberculosis, Vitamin Products, Anti Allergics, Corticosteroids, Hyper and Hypoglycemic, Others.

FAQs for the comparison of Senores Pharmaceuticals Ltd and Shukra Pharmaceuticals Ltd

Which company has a larger market capitalization, Senores Pharmaceuticals Ltd or Shukra Pharmaceuticals Ltd?

Market cap of Senores Pharmaceuticals Ltd is 4,846 Cr while Market cap of Shukra Pharmaceuticals Ltd is 1,374 Cr

What are the key factors driving the stock performance of Senores Pharmaceuticals Ltd and Shukra Pharmaceuticals Ltd?

The stock performance of Senores Pharmaceuticals Ltd and Shukra Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Senores Pharmaceuticals Ltd and Shukra Pharmaceuticals Ltd?

As of May 18, 2026, the Senores Pharmaceuticals Ltd stock price is INR ₹1052.35. On the other hand, Shukra Pharmaceuticals Ltd stock price is INR ₹31.4.

How do dividend payouts of Senores Pharmaceuticals Ltd and Shukra Pharmaceuticals Ltd compare?

To compare the dividend payouts of Senores Pharmaceuticals Ltd and Shukra Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.